Veracyte (VCYT) CFO receives restricted stock unit grants boosting holdings

Rhea-AI Filing Summary

Chambers Rebecca reported acquisition or exercise transactions in this Form 4 filing.

Veracyte, Inc. Chief Financial Officer Rebecca Chambers reported two equity compensation awards in the form of restricted stock units tied to shares of common stock. She was granted 36,181 units and 13,157 units on March 6, 2026, both at no purchase price.

Following these awards, Chambers directly holds 180,534 shares of Veracyte common stock. One award vests 25% on March 2, 2027, with the remainder vesting in equal quarterly installments, while the other vests in full on the first anniversary of the grant, in each case conditioned on continued employment through the vesting dates.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chambers Rebecca

(Last) (First) (Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		A(1)		36,181	A	$0	167,377	D
Common Stock	03/06/2026		A(2)		13,157	A	$0	180,534	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.

2. Restricted stock units awarded on March 6, 2026 vest in full on the first anniversary of the date of grant subject to continuing employment of the Reporting Person on each vesting date.

Remarks:

	/s/ Jonathan Wygant as attorney-in-fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Veracyte (VCYT) report for its CFO?

Veracyte reported that CFO Rebecca Chambers received two equity awards of restricted stock units covering 36,181 and 13,157 shares of common stock. These awards were granted at no purchase price as part of her compensation and increase her direct share holdings.

How many Veracyte (VCYT) shares does the CFO hold after the latest Form 4?

After the reported awards, CFO Rebecca Chambers directly holds 180,534 shares of Veracyte common stock. This figure reflects her updated ownership position following the two restricted stock unit grants disclosed for March 6, 2026, on the Form 4.

Are the Veracyte (VCYT) CFO’s new equity awards open-market share purchases?

No, the transactions are compensation-related grants, not open-market purchases. The Form 4 shows restricted stock unit awards with a price per share of $0.00, meaning Chambers did not buy shares in the market but received them as part of her pay package.

What are the vesting terms of the Veracyte (VCYT) CFO’s 36,181 restricted stock units?

The 36,181 restricted stock units vest 25% on March 2, 2027, with the remaining 75% vesting in equal 1/16 installments each quarter thereafter. Vesting requires Rebecca Chambers to remain employed with Veracyte on each applicable vesting date.

When do the Veracyte (VCYT) CFO’s 13,157 restricted stock units vest?

The 13,157 restricted stock units vest in full on the first anniversary of the March 6, 2026 grant date. This full vesting is subject to the condition that CFO Rebecca Chambers continues her employment with Veracyte through that one-year vesting date.

Does the Veracyte (VCYT) Form 4 show any insider share sales by the CFO?

No, the Form 4 does not report any share sales. It discloses two acquisition-type transactions coded as grants or awards of restricted stock units, with a transaction direction of “acquire” and no selling activity indicated in the transaction summary.